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depression were assessed using validated tools. Individuals 
with PSS had significantly reduced levels of physical activ-
ity [median (interquartile range, IQR) 1572 (594–3158) 
versus 3708 (1732–8255) metabolic equivalent of task 
(MET) × min/week, p < 0.001], but similar levels of sed-
entary activity [median (IQR) min 300 (135–375) versus 
343 (223–433) (MET) × min/week, p = 0.532] compared 
to healthy individuals. Differences in physical activity 
between PSS and controls increased at moderate [median 
(IQR) 0 (0–480) versus 1560 (570–3900) MET × min/
week, p < 0.001] and vigorous intensities [median (IQR) 
0 (0–480) versus 480 (0–1920) MET × min/week, 
p < 0.001]. Correlation analysis revealed a significant 
association between physical activity and fatigue, orthos-
tatic intolerance, depressive symptoms and quality of life. 
Sedentary activity did not correlate with fatigue. Stepwise 
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linear regression analysis identified symptoms of depres-
sion and daytime sleepiness as independent predictors 
of levels of physical activity. Physical activity is reduced 
in people with PSS and is associated with symptoms of 
depression and daytime sleepiness. Sedentary activity is 
not increased in PSS. Clinical care teams should explore 
the clinical utility of targeting low levels of physical activ-
ity in PSS.
Keywords Primary Sjögren’s syndrome · Physical 
activity · Patient registry · Patient-reported outcomes · 
Fatigue
Introduction
Musculoskeletal pain and fatigue are key symptoms of pri-
mary Sjögren’s syndrome (PSS) and can adversely impact 
on levels of physical activity. Indeed, individuals with PSS 
have reported that the disease impacts on their physical 
activity levels [1]. A physically active lifestyle is associ-
ated with decreased risk of cardiovascular disease, stroke, 
hypertension, type 2 diabetes, obesity, some cancers as well 
as all-cause mortality [2–4]. It is possible that people with 
PSS are at excess risk of secondary disease as a result of 
reduced physical activity in addition to the primary clinical 
diagnosis.
Very little research has been undertaken to evaluate 
physical activity levels in PSS patients. To date, a Dutch 
study has reported physical activity in people with PSS as 
its primary outcome. A report of 223 PSS patients and 67 
controls revealed that PSS patients reported less moderate 
and vigorous physical activity, but similar levels of walking 
to matched controls without PSS [5]. Although an impor-
tant study, the data are limited by the relatively small con-
trol group and is missing data on body mass index (BMI). 
Matching for BMI is important as BMI is related to physi-
cal activity [6, 7]. Another report from Sweden also sug-
gested that physical activity is reduced in PSS, although 
physical activity was not the primary outcome and the 
study is limited by a small sample size (n = 51) and use 
of tool that is not validated [8]. Furthermore, it has been 
known that physical activity behaviour varies greatly across 
different countries in population-based studies [9, 10], and 
to our knowledge, physical activity in PSS has not been 
assessed in the UK. Interestingly, no studies have reported 
whether people with PSS spend more time sedentary, 
despite the powerful role of sedentary behaviour in health 
and well-being.
The International Physical Activity Questionnaire-short 
form (IPAQ-SF) is the most widely used self-reported ques-
tionnaire for population or cohort studies of habitual physi-
cal activities which is easy to complete, and its reliability 
and validity have been established in different countries 
[11, 12].
The primary aim of this study was to assess the level of 
physical activity and sedentary behaviour in a large cohort 
of PSS patients and people without chronic disease indi-
vidually matched for age, gender and BMI. The secondary 
aims were to explore the relationships between physical 
activity and sedentary behaviour with clinical features of 
PSS.
Patients and methods
To this cross-sectional study, PSS patients and healthy con-
trol subjects were recruited from September 2009 to Sep-
tember 2011. Self-reported levels of physical activity from 
PSS patients were compared with healthy controls. Fatigue 
and other clinical aspects of PSS including disease status, 
dryness, daytime sleepiness, dysautonomia, anxiety and 
depression were also assessed.
Subject groups
All PSS patients are participants of the United Kingdom 
primary Sjögren’s syndrome registry (UKPSSR, www.
sjogrensregistry.org) [13] and were recruited from 30 par-
ticipating centres in the UK. Embedded within the design 
of the UKPSSR are several optional sub-studies aiming 
to address different clinical questions, one of which is the 
level of physical activity among PSS patients. Participants 
of the UKPSSR were given the IPAQ-SF questionnaire 
which they could choose whether to complete or not. Each 
PSS participant with complete IPAQ-SF data matched case 
by case (1:1) by sex, age (±3 years) and BMI (±3 kg/m2) 
was recruited from a community control cohort of 800 sub-
jects without clinical diagnosis of chronic disease based on 
self-reported history established by co-author Trenell.
Inclusion criteria were as follows: age over 18, fulfil 
the American European Consensus Group (AECG) classi-
fication criteria [14] and those with complete datasets for 
physical activity assessment and matched controls. Patients 
without matched controls and body mass index (BMI) data 
were excluded.
Research ethical approval was granted by the North 
West Research Ethics Committee. Informed consent was 
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obtained from all patients according to the principles of the 
Helsinki Declaration.
Measures
All clinical and laboratory data were collected prospec-
tively at the time of recruitment, and the instruments used 
were: IPAQ-SF, 100-mm visual analogue scale to deter-
mine overall fatigue, Profile of Fatigue (ProF, measures 
fatigue in PSS) [15], Epworth Sleepiness Scale (ESS, 
measures daytime sleepiness) [16], Orthostatic Grading 
Scale (OGS, measures orthostatic intolerance) [17], Com-
posite Autonomic Symptom Scale (COMPASS, measures 
autonomic symptoms) [18], EULAR Sjögren’s Syndrome 
Disease Activity Index (ESSDAI, measures disease activ-
ity) [19], EULAR Sjögren’s Syndrome Patient-Reported 
Index (ESSPRI, measures overall burden of symptoms) 
[20], EULAR Sicca Score (EULAR-SS, measures overall 
severity of dryness) [20], Hospital Anxiety and Depression 
Scale (HADS, measures anxiety and depressive symptoms) 
[21], EuroQol-5 Domain (EQ5D, measures health-related 
quality of life) [22] and Comorbidity–Polypharmacy Score 
(CPS, quantify the magnitude of comorbid conditions) [23, 
24]. To score the CPS, all the known comorbidities and 
medications that a patient has been taking were considered.
Physical activity was measured using IPAQ-SF. The 
nine-item IPAQ-SF records the time spent on physical 
activity of three intensity levels (vigorous, moderate and 
walking) as well as the time spent on sitting (referred to 
as sedentary in this study) in the past week. The data were 
processed and analysed according to the guidelines pub-
lished by the IPAQ research committee [25]. In brief, the 
metabolic equivalent of task (MET) values for each inten-
sity level of physical activity, derived from the IPAQ Reli-
ability Study [12], were multiplied by the time spent (in 
minutes/week) for each intensity level of physical activity 
to obtain the total MET values for each intensity levels of 
physical activity. The total physical activity (PA) score is 
the sum of total MET values for vigorous, moderate and 
walking activities. Sedentary time (median) was reported in 
minutes/week.
Statistical analysis
All data were analysed using IBM SPSS Statistics 19. As 
most variables were not normally distributed, Wilcoxon 
matched pairs/Mann–Whitney test was performed for com-
parisons between PSS and control groups. The PA scores 
were substantially positively skewed and were therefore log 
transformed. Pearson’s and Spearman’s correlations were 
used for correlation analysis for nonparametric and para-
metric data, respectively. To identify independent predic-
tors for physical activity, stepwise linear regression analysis 
was performed using log-transformed total PA score as the 
dependent variable.
Results
Among 688 patients recruited to the UKPSSR, 594 patients 
(86.3%) participated in the physical activity sub-study. 
Only those with complete datasets for physical activity 
assessment and matched controls (n = 273) were included 
in the analysis. Figure 1 summarizes the participant flow 
through this study.
Patient characteristics
The clinical characteristics of the PSS cohort used in this 
study and the demographics of the age-, sex- and BMI-
matched healthy controls are summarized in Table 1. The 
study cohort (“matched IPAQ-SF” group, (n = 273) dif-
fered clinically from the remaining UKPSSR cohort 
(n = 415), with the study cohort being younger, with better 
quality of life, fewer comorbidities and less overall symp-
tom burden (ESSPRI), fatigue, pain, symptoms of anxiety, 
depression and daytime sleepiness (Online Resource, Sup-
plementary table 1). There were no significant differences 
in the physical activity measures between the study group 
and those with complete IPAQ-SF datasets but without 
matched controls (“unmatched IPAQ-SF” group, n = 55), 
with the exception of age and BMI, which were expected 
because the more extreme values of the age and BMI in 
the unmatched IPAQ-SF group were the reasons for match-
ing not being achieved (Online Resource, Supplementary 
table 2). The “matched IPAQ-SF” group also has lower 
CPS score than the “unmatched IPAQ-SF” group.
Levels of physical activity were significantly reduced 
in PSS patients
The median total PA score in the PSS group was <50% 
compared to the controls (Table 1). Moderate and vigor-
ous physical activities were markedly reduced among PSS 
patients compared to the matched control group (Fig. 2). 
Levels of sedentary activity (sitting time) were similar 
between PSS patients and controls. Female patients were 
less active than male patients, but there was no difference 
in the control group (Online Resource, Supplementary 
table S3).
Relationships between physical activity levels 
and clinical features of PSS
To explore the relationships between levels of physical 
activity and clinical features of PSS, we first performed 
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a correlation analysis between total PA score and a range 
of pre-specified parameters based on potential biological 
links and data from previous studies. Total PA score cor-
related weakly but statistically significantly with physical 
fatigue (r = −0.159), mental fatigue (r = −0.135), symp-
toms of depression (r = −0.146), orthostatic intolerance 
(r = −0.124) and quality of life (r = −0.200), but none 
of the clinical features correlated with sitting time (Online 
Resource, Supplementary table S4). Stepwise linear regres-
sion analysis identified symptoms of depression and day-
time sleepiness as independent predictors of total PA score 
(Table 2). However, these two predictors accounted for 
only approximately 4.5% of the variance in total PA score 
(p = 0.047). Fatigue was a predictor of vigorous and mod-
erate intensities of physical activity, whereas symptoms of 
depression, anxiety and daytime sleepiness were predic-
tors of physical activity of moderate intensity. Symptoms 
of dryness, depression and BMI predicted walking activity 
(Table 2).
Discussion
In this study, we showed that self-reported physical activ-
ity levels were significantly lower among PSS patients, 
particularly for physical activities of vigorous and moder-
ate intensities, compared to age-, sex- and BMI-matched 
healthy controls. However, levels of sedentary activity 
(sitting time) were not increased in PSS patients. Reduced 
levels of total physical activity score were independently 
associated with symptoms of depression and daytime 
sleepiness.
Our data reveal a decrease in physical activity in peo-
ple with PSS against a well-matched control group. The 
data build on previous reports, supporting the associa-
tion of PSS with reduced moderate and vigorous physical 
UKPSSR Cohort (n=688)
Excluded:
• Missing BMI data (n=7)
• “Incomplete or Unusable” IPAQ data* (n =259)
Participants of physical activity sub-study (n=594)
Complete IPAQ –SF data (n=328)
Included in analysis:
Matched IPAQ-SF group (n=273)
Excluded:
• Unmatched IPAQ-SF group (n=55)
Community control cohort (n=800)
Included in analysis:
Matched healthy control group (n=273)
PSS patients Controls
Matched on gender, age and BMI
(n=273)
Fig. 1  Summary of the participant flow of the study. *The majority 
(~70%) of the “Incomplete/unusable” data were “unusable” because 
the participants had responded “Don’t know/Not sure” to the ques-
tion on “how much time spent on the physical activity”, the remain-
ing were “unusable” because data on the number of days or hours/
minutes spending on the physical activity were missing, unclear or 
contradictory
Table 1  Characteristics of the primary Sjögren’s syndrome (PSS) 
cohort and matched healthy control
All values are presented as medians (interquartile ranges)
kg/m2 kilogram per metre squared, min minutes, MET metabolic 
equivalent of task, min/wk minutes per week
PSS cohort Healthy control p
Sample size 273 273
Female/male, n 254/19 254/19
Age 57 (47–65) 58 (47–65) 0.310
Body mass index 
(kg/m2)
25 (23–28) 25 (23–27) 0.285
Sitting time (min) 300 (135–375) 343 (223–433) 0.454
Vigorous PA 
(MET × min/wk)
0 (0–480) 480 (0–1920) <0.001
Moderate PA 
(MET × min/wk)
0 (0–480) 1560 (570–3930) <0.001
Walking 
(MET × min/wk)
792 (396–2079) 990 (462-3020) 0.012
Total PA score 
(MET × min/wk)
1572 (594–3158) 3708 (1732–8255) <0.001
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activity [5], but add further by demonstrating that this is not 
confounded by BMI. Our patients were recruited from 30 
centres (with a mixture of teaching hospitals and district 
general hospitals) across the UK, increasing the ecological 
validity of the data. Sedentary activity is associated with 
adverse health effects independent of those from decreased 
levels of overall physical activity or higher-intensity physi-
cal activity [26, 27]. Interestingly, the decrease in physical 
activity in the present study was not accompanied by an 
increase in sedentary behaviour. The similarity in sedentary 
behaviour between the PSS and control groups does not 
support the belief that PSS patients spend more time sit-
ting. Combined, these data suggest that patients are moving 
as much as their healthy counterparts, but when they are 
active they are not working as hard. As such, patients with 
PSS may be exposed to excess risk of developing second-
ary chronic disease as a result of their low levels of physi-
cal activity and this should be targeted therapeutically.
Despite the weak association, our study is the first to 
demonstrate the relationship between physical activity and 
daytime sleepiness in PSS, which together with symptoms 
of depression, predicted lower levels of physical activities, 
mainly those at moderate intensity levels. In a previous 
study, excessive daytime sleepiness, defined as the propen-
sity to fall asleep at a time when the individual would usu-
ally be awake and alert, was more prevalent in PSS patients 
than in healthy controls and was associated with mental 
and physical fatigue. Sleep disturbances in PSS, anxiety, 
nocturia and sicca problems, were also more prevalent, 
but only insomnia correlated with daytime sleepiness and 
depression had some impact on daytime sleepiness [28]. 
In a study by Zafar et al., PSS patients had higher level 
of daytime sleepiness and twice the frequency of obstruc-
tive apnoeas and hypopneas compared with control sub-
jects but no significant correlations were found between 
these parameters and sleepiness scores [29]. Walker et al. 
Fig. 2  Vigorous, moderate, total and walking physical activity levels in primary Sjögren’s syndrome (PSS) cohort and healthy controls. PA 
physical activity
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[30] found that PSS patients have more severe symptoms 
of daytime sleepiness than patients with osteoarthritis, 
independent of nocturia. Daytime sleepiness in PSS is also 
associated with impaired functional status [31], autonomic 
symptoms [32] and decreased quality of life [33]. However, 
daytime sleepiness and depression can be interrelated and 
should be viewed concurrently.
Depression is a key determinant of EQ5D utility values 
in a large PSS cohort in the UK and also has a significant 
correlation with fatigue [33]. Depression is an independent 
predictor of cognitive symptoms [34], strongly correlates 
with functional disability [31] and leads to more physician 
visits and work disability in PSS patients [35]. Strömbeck 
et al. [8] did not find an association between depression 
and an indirect measure of aerobic capacity. In contrast, our 
study demonstrated that depression may be an independ-
ent predictor of decreased levels of self-reported physical 
activity in PSS. Our data suggest that identifying excessive 
daytime sleepiness and depressive symptoms as well as 
their contributing factors may be important in achieving a 
more physically active lifestyle for some people living with 
PSS.
The inverse relationship between fatigue and moder-
ate/vigorous physical activity levels is perhaps unsurpris-
ing and has been reported in healthy populations and other 
chronic conditions [36–39]. Whether there is a causal 
link between fatigue and physical activity levels remains 
unclear and cannot be addressed based on the data gen-
erated from this study. Strömbeck et al. reported that 
women with PSS have decreased physical capacity and 
experienced more pain during the shoulder mobility test. 
Furthermore, diminished aerobic capacity correlated with 
symptoms of fatigue experienced [8]. Interestingly, in a 
small group of PSS patients, Nordic walking for 45 min 
thrice weekly for 12 weeks improved aerobic capacity 
and reduced symptoms of fatigue and depression, but not 
quality of life [40]. More recently, Wouters et al. [5] have 
shown that in PSS patients’ lower physical activity, higher 
activity avoidance and somatic focus were associated with 
more severe symptoms of fatigue. These observations 
implied that programmes designed to increase the levels of 
physical activity may ameliorate the symptoms of fatigue 
and depression.
The association between symptoms of dryness and 
physical activity levels is a novel finding and could be a 
consequence of the increased walking time compared with 
vigorous and moderate activities in patients with higher 
symptoms of dryness. Further studies are needed to explore 
the underlying mechanisms of association between sicca 
symptoms and physical activity levels.
Table 2  Stepwise regression 
analysis of independent 
correlations of total and various 
intensity levels of physical 
activity of primary Sjögren’s 
syndrome cohort
PA physical activity, HADS Hospital Anxiety and Depression Scale, ESS Epworth Sleepiness Scale, ProF 
Profile of Fatigue, VAS visual analogue scale
Coefficients
Unstandardized Standardized
B SE Beta t p R R2 Adj. R2
(a) Total PA score 0.211 0.045 0.036
(Constant) 3.191 0.075 54.148 <0.001
Depression (HADS) −0.031 0.010 −0.218 −3.105 0.002
Daytime sleepiness (ESS) 0.016 0.008 0.140 2.000 0.047
(b) Vigorous PA 0.308 0.095 0.087
(Constant) 3.019 0.484 6.234 <0.001
Physical fatigue (ProF) −0.210 0.55 −0.244 −3.848 <0.001
Age −0.024 0.008 −0.189 −2.977 0.003
(c) Moderate PA 0.346 0.120 0.104
(Constant) 1.047 0.222 4.709 <0.001
Overall fatigue (VAS) −0.012 0.004 −0.228 −2.790 0.006
Daytime sleepiness (ESS) 0.073 0.021 0.246 3.452 0.001
Depression (HADS) −0.093 0.034 −0.248 −2.781 0.006
Anxiety (HADS) 0.086 0.027 0.264 3.209 0.002
(d) Walking 0.289 0.084 0.071
(Constant) 3.321 0.320 10.382 <0.001
EULAR Sicca Score 0.065 0.018 0.238 3.538 <0.001
Depression (HADS) −0.029 0.012 −0.161 −2.390 0.018
Body mass index −0.028 0.012 −0.149 −2.321 0.021
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In this study, symptoms of depression and daytime 
sleepiness accounted for merely 4.5% of the variance of 
total physical activity levels. Symptoms of pain, autonomic 
dysfunction and anxiety are well described among PSS 
patients and may also affect physical activity levels. How-
ever, although fatigue and orthostatic intolerance inversely 
correlated with total physical activity score, they were not 
identified as independent predictors in regression analysis. 
Given the link between reduced physical activity levels and 
adverse health outcomes [2–4] as well as diminished qual-
ity of life [41–43], further studies to improve our under-
standing of the contributing factors to reduced physical 
activity in PSS and to devise strategies to increase physical 
activity levels in PSS are warranted.
The present study has limitations. Formal sample size 
calculation was not performed; nevertheless, our sam-
ple is greater than the previous study [5] and is matched 
case by case by sex, age and BMI. Direct measurements 
of physical activity were not performed; however, IPAQ-
SF scores have been shown to correlate well with actual 
physical activity levels [11, 12]. Furthermore, since physi-
cal activity levels of both study groups were estimated 
using the same instrument, we anticipate that our obser-
vation of reduced physical activity levels in PSS rela-
tive to their matched healthy controls remains valid upon 
objective measurements. Only ~40% of the entire cohort 
had complete and matched IPAQ-SF data for analysis, 
and the study cohort differed from the remaining PSS 
cohort—with the study cohort having better quality of life 
and lower levels of fatigue, disease activity, fewer comor-
bidities, less symptom burden, dryness, orthostatic intoler-
ance, anxiety, symptoms of depression and being younger. 
Since fatigue, depression and orthostatic intolerance are 
inversely correlated with the levels of physical activity, we 
believe that the physical activity levels of PSS patients of 
the entire cohort might be even lower. External validation 
of our findings with an independent cohort has not been 
conducted.
In conclusion, physical activity is reduced in people with 
PSS without a concomitant increase in sedentary activity. 
Symptoms of depression and daytime sleepiness may be 
predictors of physical activity in PSS. Given the risks of 
developing secondary chronic disease as a result of low lev-
els of physical activity, clinicians should explore the clini-
cal utility of increasing physical activity as part of a holistic 
management package of PSS.
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